Bryan Calcote, MD
Internal Medicine · Brookhaven, MSNPI 1073622999
Payments from drug & device makers
Across 415 payments — averaging $14.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$718
- Johnson & Johnson$660
- AstraZeneca$568
- Lilly USA, LLC$543
- Pfizer$439
- Amgen$430
- plus $3K from 27 others
What the payments were for
- Food & beverage$5,849100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $718 |
| Johnson & Johnson | 42 | $660 |
| AstraZeneca | 33 | $568 |
| Lilly USA, LLC | 35 | $543 |
| Pfizer | 59 | $439 |
| Amgen | 27 | $430 |
| Merck | 27 | $380 |
| Novartis | 20 | $324 |
| AbbVie(2 entities) | 23 | $309 |
| Boehringer Ingelheim | 17 | $252 |
| Bayer | 16 | $251 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $211 |
| Corcept Therapeutics | 5 | $100 |
| Sanofi-aventis U.S. LLC | 6 | $79 |
| Dexcom, Inc. | 4 | $69 |
| Abbott | 3 | $67 |
| GSK | 4 | $57 |
| Astellas Pharma US Inc | 4 | $52 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Currax Pharmaceuticals LLC | 3 | $45 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Exact Sciences | 2 | $32 |
| Shield Therapeutics Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Reprise Biomedical, Inc. | 1 | $17 |
| Fidia Pharma USA Inc. | 4 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$5,867 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 124 | $111,508 |
| OzempicSemaglutide | 102 | $105,977 |
| EliquisApixaban | 118 | $98,735 |
| FarxigaDapagliflozin Propanediol | 80 | $76,443 |
| TrulicityDulaglutide | 59 | $76,367 |
| XareltoRivaroxaban | 100 | $73,558 |
| JanuviaSitagliptin Phosphate | 71 | $73,434 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $35,369 |
| TradjentaLinagliptin | 35 | $31,549 |
| LinzessLinaclotide | 35 | $30,377 |
| RybelsusSemaglutide | 18 | $30,001 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $28,141 |
| InvokanaCanagliflozin | 39 | $26,828 |
| MounjaroTirzepatide | 17 | $16,806 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $13,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $252 | $143,057159 claims |
| Novo NordiskOzempic, Rybelsus | $718 | $135,977120 claims |
| PfizerEliquis, Dilantin | $439 | $101,106130 claims |
| Johnson & JohnsonXarelto, Invokana | $660 | $100,386139 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $543 | $93,17376 claims |
| AstraZenecaFarxiga | $568 | $76,44380 claims |
| MerckJanuvia | $380 | $73,43471 claims |
| AbbVieLinzess, Synthroid | $309 | $37,703154 claims |
| GSKTrelegy Ellipta | $57 | $13,96014 claims |
| NovartisEntresto | $324 | $12,32817 claims |
| BayerKerendia | $251 | $6,60011 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $12 | $3,95064 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Brookhaven
- James HallBrookhaven$4.8M
- Ramiro MontalvoBrookhaven$10K
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.